P61
In the name of progress, disease control and elimination: medical research, global funds and local people

Convenors:
Sarah O'Neill (Université Libre de Bruxelles)
Discussant:
Paul Wenzel Geissler (University of Oslo), Koen Peeters (Institute of Tropical Medicine)
Location:
Chrystal Macmillan Building, Seminar Room 5
Start time:
21 June, 2014 at 9:00
Session slots:
2

Short abstract:

This panel invites papers on biomedical research and trials in 'wealthy nations' and the 'developing world'. Themes like progress, poverty and wealth will be discussed in conjunction with topical themes in public health like disease control and elimination, mass drug treatment and patient adherence.

Long abstract:

Extensive amounts of funding are invested in medical research all over the world. Some biomedical research seems to be progressing slowly (E.g. HIV/AIDS, Nodding Syndrome) whereas other research strands are said to be in the 'elimination' stages (e.g. Polio, Malaria). People in more impoverished places are struck harder by diseases that are endemic to their areas. Based on the logic that data on poorly understood diseases needs to be collected in endemic areas and will help to further develop treatments and prevention, clinical trial research also takes place in the poorest parts of the world. This panel engages with biomedical research, clinical trials and global health agendas in 'wealthy nations' and the 'developing world' to explore topical themes in this field such as 'patient benefit' versus 'satisfaction', 'adherence to treatment', 'mass drug administration', 'disease elimination' and 'acceptability of trial research and interventions'. The papers particularly explore: • The rhetoric of the benefit of health interventions and clinical research in contrast to patient experience • Silenced inequalities and power differentials in transnational collaborations • Health seeking behavior, education and 'ignorance' The panel also asks what the role of anthropology should be in informing disease control and elimination programmes in the face of 'killer diseases', 'intelligent parasites', drug resistance and the need to further engage with complex health issues in a globalized world.